miRecule CEO Anthony D. Saleh, Ph.D. guests on BioTalk to discuss his company, his many roles in startup companies, and being an Entrepreneur in Residence with BHI
Anthony is a biotech entrepreneur and having served in a variety of roles in startup companies. He is currently the CEO of miRecule, Inc., but also helped found MIMETAS US, and Birich Technologies. As an “Entrepreneur in Residence” at BioHealth Innovation, he has consulted for over a dozen biotech companies. In this role, he led technology diligence, market analysis and business and product development efforts. He also participated in funding raises for two companies, and performed scouting efforts for Roche and MedImmune, leading to several academic collaborations. As the President of MIMETAS US (a startup affiliate of the Dutch company Mimetas BV), he raised over $4.5 M in non-dilutive funding and over $1 M in commercial partnerships to develop organ-on-a-chip based drug discovery models. Dr. Saleh has more than 15 years of experience in microRNA research, nucleic acid chemistry and the design of therapeutic oligonucleotides at Johns Hopkins University, The National Institutes of Health, and in the private sector. Dr. Saleh has raised about $5 M in dilutive and no-dilutive funding directed to gain IND approval for miRecule’s lead therapeutic MC-30.